This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
G Abraham , R Milev , J Stuart Lawson (2006). T3 augmentation of SSRI resistant depression. Journal of Affective Disorders 91, 211–215.
CB Aiken (2007). Pramipexole in psychiatry: a systematic review of the literature. Journal of Clinical Psychiatry 68, 1230–1236.
LL Altshuler , M Bauer , MA Frye , MJ Gitlin , (2001). Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. American Journal of Psychiatry 158, 1617–1622.
IM Anderson (1998). SSRIs vs. tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depression and Anxiety 7 (Suppl. 1), 11–17.
IM Anderson (2000). Selective serotonin reuptake inhibitors vs. tricyclic antidepressants: a meta-analysis of efficacy and tolerability. Journal of Affective Disorders 58, 19–36.
J Angst , A Gamma , R Sellaro , PW Lavori , (2003). Recurrence of bipolar disorders and major depression. A life-long perspective. European Archives of Psychiatry and Clinical Neuroscience 253, 236–240.
JS Ballon , D Feifel (2006). A systematic review of modafinil: Potential clinical uses and mechanisms of action. Journal of Clinical Psychiatry 67, 554–566.
L Barbosa , M Berk , M Vorster (2003). A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. Journal of Clinical Psychiatry 64, 403–407.
LL Carpenter , S Yasmin , LH Price (2002). A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biological Psychiatry 51, 183–188.
A Cipriani , TA Furukawa , G Salanti , JR Geddes , (2009). Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373, 746–758.
CU Correll , S Leucht , JM Kane (2004). Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of one-year studies. American Journal of Psychiatry 161, 414–415.
MH Corrigan , AQ Denahan , CE Wright , RJ Ragual , (2000). Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depression and Anxiety 11, 58–65.
NA Crossley , M Bauer (2007). Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. Journal of Clinical Psychiatry 68, 935–940.
C DeBattista , K Doghramji , MA Menza , MH Rosenthal , (2003). Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. Journal of Clinical Psychiatry 64, 1057–1064.
C DeBattista , J Hawkins (2009). Utility of atypical antipsychotics in the treatment of resistant unipolar depression. CNS Drugs 23, 369–377.
C DeBattista , A Lembke , HB Solvason , R Ghebremichael , (2004). A prospective trial of modafinil as an adjunctive treatment of major depression. Journal of Clinical Psychopharmacology 24, 87–90.
S Elgamal , G MacQueen (2008). Galantamine as an adjunctive treatment in major depression. Journal of Clinical Psychopharmacology 28, 357–359.
M Fava , AJ Rush , SR Wisniewski , AA Nierenberg , (2006). A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. American Journal of Psychiatry 163, 1161–1172.
M Fava , ME Thase , C DeBattista (2005). A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. Journal of Clinical Psychiatry 66, 85–93.
D Fergusson , S Doucette , K Cranley Glass , S Shapiro , (2005). Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomized controlled trials. British Medical Journal 330, 396.
JC Fournier , RJ DeRubeis , SD Hollon , S Dimidjian , (2010). Antidepressant drug effects and depression severity: a patient-level meta-analysis. Journal of the American Medical Association 303, 47–53.
G Gartlehner , BN Gaynes , RA Hansen , P Thieda , (2008). Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Annals of Internal Medicine 149, 734–750.
JR Geddes , SM Carney , C Davies , TA Furukawa , (2003). Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 361, 653–661.
RD Gibbons , CH Brown , K Hur , SM Marcus , (2007). Early evidence on the effects of regulators’ suicidality warnings on SSRI prescriptions and suicide in children and adolescents. American Journal of Psychiatry 164, 1356–1363.
RD Gibbons , K Hur , DK Bhaumik , JJ Mann (2005). The relationship between antidepressant medication use and rate of suicide. Archives of General Psychiatry 62, 165–172.
RD Gibbons , K Hur , DK Bhaumik , JJ Mann (2006). The relationship between antidepressant prescription rates and rate of early adolescent suicide. American Journal of Psychiatry 163, 1898–1904.
GM Goodwin , R Emsley , S Rembry , F Rouillon , (2009). Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry 70, 1128–1137.
F Guzzetta , L Tondo , F Centorrino , RJ Baldessarini (2007). Lithium treatment reduces suicide risk in recurrent major depressive disorder. Journal of Clinical Psychiatry 68, 380–383.
R Hansen , B Gaynes , P Thieda , G Gartlehner , (2008). Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants. Psychiatric Services 59, 1121–1130.
K Hashimoto (2009). Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Research Reviews 61, 105–123.
PE Holtzheimer 3rd, TW Meeks , ME Kelley , M Mufti , (2008). A double blind, placebo-controlled pilot study of galantamine augmentation of antidepressant treatment in older adults with major depression. International Journal of Geriatric Psychiatry 23, 625–631.
DV Iosifescu , AA Nierenberg , D Mischoulon , RH Perlis , (2005). An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder. Journal of Clinical Psychiatry 66, 1038–1042.
L Judd , HS Akiskal , JD Maser , PJ Zeller , (1998). A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Journal of Affective Disorders 50, 97–108.
MB Keller , PW Lavori , CE Lewis , GL Klerman (1983). Predictors of relapse in major depressive disorder. Journal of the American Medical Association 250, 3299–3304.
N Kennedy , ES Paykel (2004). Residual symptoms at remission from depression: impact on long-term outcome. Journal of Affective Disorders 80, 135–144.
SH Kennedy , S Rizvi , K Fulton , J Rasmussen (2008). A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. Journal of Clinical Psychopharmacology 28, 329–333.
RC Kessler , P Berglund , O Demler , R Jin , (2003). The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). Journal of the American Medical Association 289, 3095–3105.
A Khan , RM Leventhal , SR Khan , WA Brown (2002). Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. Journal of Clinical Psychopharmacology 22, 40–45.
E Lauterbach , W Felber , B Muller-Oerlinghausen , B Ahrens , (2008). Adjunctive lithium treatment in the prevention of suicidal behaviour in depressive disorders: a randomised, placebo-controlled, 1-year trial. Acta Psychiatrica Scandinavica 118, 469–479.
AC Leon (2007). The revised warning for antidepressants and suicidality: unveiling the black box of statistical analyses. American Journal of Psychiatry 164, 1786–1789.
AC Leon , DA Solomon , TI Mueller , J Endicott , (2003). A 20-year longitudinal observational study of somatic antidepressant treatment effectiveness. American Journal of Psychiatry 160, 727–733.
PJ McGrath , AY Khan , MH Trivedi , JW Stewart , (2008). Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report. Journal of Clinical Psychiatry 69, 1847–1855.
PJ McGrath , JW Stewart , M Fava , MH Trivedi , (2006). Tranylcypromine vs. venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. American Journal of Psychiatry 163, 1531–1541.
FJ McMahon , S Buervenich , D Charney , R Lipsky , (2006). Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. American Journal of Human Genetics 78, 804–814.
AL Montejo , N Prieto , A Terleira , J Matias , (2010). Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale. Journal of Psychopharmacology 24, 111–120.
RT Mulder , PR Joyce , CM Frampton , SE Luty , (2008). Antidepressant treatment is associated with a reduction in suicidal ideation and suicide attempts. Acta Psychiatrica Scandinavica 118, 116–122.
A Nakagawa , MF Grunebaum , SP Ellis , MA Oquendo , (2007). Association of suicide and antidepressant prescription rates in Japan, 1999–2003. Journal of Clinical Psychiatry 68, 908–916.
JC Nelson , GI Papakostas (2009). Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. American Journal of Psychiatry 166, 980–991.
AA Nierenberg , AH Farabaugh , JE Alpert , J Gordon , (2000). Timing of onset of antidepressant response with fluoxetine treatment. American Journal of Psychiatry 157, 1423–1428.
AA Nierenberg , GI Papakostas , T Petersen , HD Montoya , (2003). Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants. Journal of Clinical Psychopharmacology 23, 92–95.
GI Papakostas (2009). The role of S-adenosyl methionine in the treatment of depression. Journal of Clinical Psychiatry 70 (Suppl. 5), 18–22.
GI Papakostas , CH Homberger , M Fava (2008). A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Journal of Psychopharmacology 22, 843–848.
GI Papakostas , D Mischoulon , I Shyu , JE Alpert , (2010). S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. American Journal of Psychiatry 167, 942–948.
GI Papakostas , RH Perlis , MJ Scalia , TJ Petersen , (2006). A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. Journal of Clinical Psychopharmacology 26, 56–60.
GI Papakostas , T Peterson , KG Sklarsky , AA Nierenberg , (2007 b). Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. Psychiatry Research 149, 195–200.
GI Papakostas , ME Thase , M Fava , JC Nelson , (2007). Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biological Psychiatry 62, 1217–1227.
RH Perlis , P Moorjani , J Fagerness , S Purcell , (2008). Pharmacogenetic analysis of genes implicated in rodent modesls of antidepressant response: association of TREK 1 and treatment resistance in the STAR(*)D study. Neuropsychopharmacology 33, 2810–2819.
RH Perlis , A Patrick , JW Smoller , PS Wang (2009). When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study. Neuropsychopharmacology 34, 2227–2236.
L Pintor , C Gasto , V Navarro , X Torres , (2003). Relapse of major depression after complete and partial remission during a 2-year follow-up. Journal of Affective Disorders 73, 237–244.
NA Rasmussen , P Schroder , LR Olsen , M Brodsgaard , (2005). Modafinil augmentation in depressed patients with partial response to antidepressants: a pilot study on self-reported symptoms covered by the Major Depression Inventory (MDI) and the Symptoms Checklist (SCL-92). Nordic Journal of Psychiatry 59, 173–178.
HG Ruhe , J Huyser , JA Swinkels , AH Schene (2006). Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. Journal of Clinical Psychiatry 67, 1836–1855.
AJ Rush , MH Trivedi , SR Wisniewski , AA Nierenberg , (2006 a). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. American Journal of Psychiatry 163, 1905–1917.
AJ Rush , MH Trivedi , SR Wisniewski , JW Stewart , (2006 b). Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. New England Journal of Medicine 354, 1231–1242.
AJ Rush , SR Wisniewski , D Warden , JF Luther , (2008). Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. Archives of General Psychiatry 65, 870–880.
G Sanacora (2009). Do glutamatergic agents represent a new class of antidepressant drugs? Part 1. Journal of Clinical Psychiatry 70, 1473–1474.
F Schindler , IG Anghelescu (2007). Lithium vs. lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study. International Clinical Psychopharmacology 22, 179–182.
HB Simpson , JC Nee , J Endicott (1997). First-episode major depression: few sex differences in course. Archives of General Psychiatry 54, 633–639.
DA Solomon , MB Keller , AC Leon , TI Mueller , (2000). Multiple recurrences of major depressive disorder. American Journal of Psychiatry 157, 229–233.
SM Stahl , M Fava , MH Trivedi , A Caputo , (2010). Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial. Journal of Clinical Psychiatry 71, 616–626.
MH Trivedi , M Fava , SR Wisniewski , ME Thase (2006). Medication augmentation after the failure of SSRIs for depression. New England Journal of Medicine 354, 1243–1252.
M Versiani , R Moreno , CJ Ramakers-van Moorsel , AJ Schutte (2005). Comparative Efficacy Antidepressants Study Group. Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients. CNS Drugs 19, 137–146.
AG Wade , TE Schlaepfer , HF Andersen , CD Kilts (2009). Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD). Journal of Psychiatric Research 43, 568–575.
KL Weihs , T Houser , SR Batey , JA Ascher , (2002). Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression. Biological Psychiatry 51, 753–761.
J Zajecka , A Schatzberg , S Stahl , A Shah , (2010). Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychopharmacology 30, 135–144.
CA Zarate Jr, JB Singh , PJ Carlson , NE Brutsche , (2006 a). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry 63, 856–864.
CA Zarate , JB Singh , JA Quiroz , G De Jesus , (2006 b). A double-blind, placebo-controlled study of memantine in the treatment of major depression. American Journal of Psychiatry 163, 153–155.
M Zimmerman , MA Posternak , I Chelminski (2002). Symptom severity and exclusion from antidepressant efficacy trials. Journal of Clinical Psychopharmacology 22, 610–614.